ScPharmaceuticals Hopes To Win Payer Favor As It Prepares For Furoscix Resubmission
The company announced interim results of the FREEDOM-HF study showing nearly $18,000 in savings per heart failure patient.
You may also be interested in...
Keeping Track: J&J Amivantamab, Infectious Disease Agents From Iterum, VBI And Atox Submitted; Another Furoscix CRL
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Keeping Track: Keytruda Adds Two New Uses, Furoscix ‘Patch Pump’ Gets A CRL, And Nightstar Nabs An RMAT
The latest drug development news and highlights from our US FDA Performance Tracker.
Deal Snapshot: The nearly $700m deal gives Vertex, already with a major foothold in CRISPR, access to Mammoth’s ultra-compact gene-editing technology in two diseases.